Anti-IFNAR1 antibodies

An antibody or antigen-binding fragment thereof comprising heavy chain HCDR1, HCDR2 and HCDR3, and light chain LCDR1, LCDR2 and LCDR3, wherein

• the HCDR1 comprises the sequence of SX1WX19N (SEQ ID NO:1),
• the HCDR2 comprises the sequence of KIDPSDSEX2X20X21NQKFX22D (SEQ ID NO:2),
• the HCDR3 comprises the sequence of GGX3IX4X5DYDX6AX-DY (SEQ ID NO:3),
• the LCDR1 comprises the sequence of KX23SEVIYNRLA (SEQ ID NO:4),
• the LCDR2 comprises the sequence of GATX24LEX25 (SEQ ID NO:5), and
• the LCDR3 comprises the sequence of QQYWX8X9PFT (SEQ ID NO:6),
• wherein X1 is Y or F, X2 is T or I, X3 is R or G, X4 is S or Y, X5 is F or Y, X6 is A or G, X7 is L or M, X8 is N or S, X9 is K or S, X19 is M or L, X20 is H or R, X21 is F or Y, X22 is R or K, X23 is S or A, X24 is T or S, X25 is S or T,
• and wherein the antibody or antigen-binding fragment thereof is capable of specifically binding to human interferon alpha receptor 1 (human IFNAR1),
• and wherein the antibody or antigen-binding fragment thereof binds to a first fragment of amino acid residues 127-227 of human IFNAR1 and a second fragment of amino acid residues 231-329 of human IFNAR1;
• and is capable of specifically binding to a truncated human IFNAR1 absent of:
• a) amino acid residues 32-126, and b) amino acid residues 331-432;
• and wherein the antibody or antigen-binding fragment thereof inhibits IFNα- and IFNω-mediated human IFNAR1 activation;
• and does not inhibit IFNβ-mediated human IFNAR1 activation, wherein the IFNα encompasses all subtypes of IFNα;
• and wherein sequence of the human IFNAR1 is human IFNAR1 protein (NCBI Ref Seq No. NP_000620.2).